Targets › IL1R1
3 programs from 3 companies in 22 trials: 13 Phase 2, 5 Phase 3, 4 Phase 1; Cardiovascular, Oncology, Other; next expected readout Dec 2026.
Receptor for IL1A, IL1B and IL1RN. After binding to interleukin-1 associates with the coreceptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. (UniProt, P14778)
Open in Phaseline: the race on IL1R1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Tiantan Hospital | Y-4 tablets Integrin alpha-IIb/beta-3 inhibitor | PDE3A, ITGB3, ITGA2B, IL1R1 | Phase 3 | Ischemic Stroke, Acute; Aneurysmal Subarachnoid Hemorrhage; Acute Ischemic Stroke; Stroke Acute … | Dec 2026 |
| Swedish Orphan Biovitrum | Anakinra Interleukin-1 receptor antagonist | IL1R1 | Phase 3 | Still's Disease, Juvenile Onset; FMF; Kawasaki Disease; Premature Infants … | – |
| Buzzard Pharmaceuticals | isunakinra IL-1 receptor 1 inhibitor | IL1R1 | Phase 2 | Colorectal Cancer Metastatic; Triple-Negative Breast Cancer (TNBC) | Jun 2027 |
Stroke Acute (2) Still's Disease, Juvenile Onset (1) FMF (1) Kawasaki Disease (1) Premature Infants (1) Autoimmune Inner Ear Disease (1) Heart Failure (1) Pancreatic Adenocarcinoma (1) B Cell ALL (1) Dengue (1) Post-Acute COVID-19 Syndrome (1) Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) (1)
protein or peptide (2), small molecule (1)
Swedish Orphan Biovitrum (1) Beijing Tiantan Hospital (1) Buzzard Pharmaceuticals (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.